Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.43 |
| ▸ | FEN1 | P39748 | 9/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23347204 | 0.81 | ALOX5AP (0.56) | ALOX5APFEN1MAOBKCNA5 | |
| SCHEMBL2948017 | 0.80 | ALOX5AP (0.54) | DPP4NOS3NOS1NOS2ALOX5AP | |
| SCHEMBL28936838 | 0.79 | ALOX5AP (0.44) | ALOX5APFEN1ADRA2CMAOBKCNA5 | |
| SCHEMBL3723618 | 0.79 | DPP4 (0.69) | DPP4NOS3NOS1NOS2MAOB | |
| SCHEMBL2393685 | 0.78 | KCNA5 (0.43) | ALOX5APFEN1MAOBKCNA5 | |
| SCHEMBL5992838 | 0.78 | PTPRC (0.47) | DPP4ALOX5APFEN1CD274TAAR1 | |
| SCHEMBL16814898 | 0.78 | DPP4 (0.62) | DPP4NOS3NOS1NOS2ADRA2C | |
| SCHEMBL3949417 | 0.77 | KCNA5 (0.45) | ALOX5APFEN1MAOBKCNA5 | |
| SCHEMBL6048497 | 0.77 | SLC6A4 (0.54) | F10 | |
| SCHEMBL22910540 | 0.77 | LTA4H (0.45) | ALOX5APFEN1TAAR1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | DPP4 4206/4885NOS3 2834/4885NOS1 2196/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | DPP4 4521/4885NOS3 1043/4885NOS1 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.